Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders← Volver a ensayos
AbiertoNCT04416178Ver en ClinicalTrials.gov ↗

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

Mostrando el original en inglés

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

Afección específica por raza/etnia

Fase

No reportado

Inscripción

352 (estimado)

Rango de edad

13 Years to —

Sexo

ALL

Resumen

The primary objectives of this prospective mixed-method interview study are to use semi-structured interviews in parents of sickle cell disease (SCD) patients to describe parental attitudes of research involving genomic sequencing, including concerns about participation and expectations from researchers and second, to use surveys to quantitatively measure genetic/genomic knowledge, trust in health care provider, and literacy/numeracy ability in parents of children with SCD and adolescents with SCD. Secondary objectives are development of a web-based tool about treatment options for SCD that fosters patient-clinician communication and promotes shared decision-making. The web-based tool will undergo usability and pilot testing to ensure it is accessible to families and provide data about strategies for integrating into clinical conversations about treatment options. Investigators will use the data generated to reduce the risk of misunderstanding about DNA and genetic research and build strong relationships between SCD families and researchers in the future. The project will design educational information and study materials to help parents of children with SCD understand important details about genomic medicine in SCD care.

Mostrando el original en inglés

Afecciones estudiadas

Sickle Cell Disease

Patrocinadores

St. Jude Children's Research HospitalPrincipal
National Heart, Lung, and Blood Institute (NHLBI)Colaborador

Ubicaciones del estudio

St. Jude Children's Research Hospital

Memphis, Tennessee

Liza M. Johnson, MD, MPH, MSB, CONTACT